Clinical Trial

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

Recruiting Phase 1/2

Summary

The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma. The main questions the study aims to answer are: * Progression-free and overall survival of patients receiving this combination; * Quality of Life (QOL); and * Tumor response on imaging The participants will take APG-157 daily by dissolving two pastilles in their mouth at around breakfast, lunch and dinner time (total of six pastilles per day). The pastilles dissolve in the mouth. The participants will continue to receive Bevacizumab as standard of care.

Protocol Amendment History 5 amendments

This ClinicalTrials.gov record has been amended 5 times since 2023-08-23; most recent amendment 2026-06-04.

Status change: Not Yet Recruiting → Recruiting 2023-12-12

Trial Details

NCT Number	NCT06011109
Lead Sponsor	Aveta Biomics, Inc.
Conditions	Glioma, Glioblastoma Multiforme
Enrollment	30 participants
Start Date	2023-12-13
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-08